Denali Therapeutics
Open
$18.83
Prev. Close
$18.83
High
$18.84
Low
$18.83
Market Snapshot
$2.73B
-5.3
-2.58
503
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 503 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. The company has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). The company is also exploring programs in oncology, inflammation, and other diseases.
emptyResult
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 503 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. The company has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). The company is also exploring programs in oncology, inflammation, and other diseases.
Recently from Cashu
Denali Therapeutics Secures FDA Accelerated Approval for Avlayah, Enhancing Biotech Credibility
Denali Therapeutics Achieves FDA Accelerated Approval for Avlayah Denali Therapeutics Inc. reaches a notable milestone with the U.S. Food and Drug Administration's (FDA) recent accelerated approval fo…
Denali Therapeutics Advances Neurodegenerative Disease Research Amid Market Instability
Denali Therapeutics Focuses on Advancements in Neurodegenerative Disease Research Amid Market Volatility Denali Therapeutics, a biotechnology company specializing in therapies for neurodegenerative di…
Denali Therapeutics Advances Neurological Treatments Despite Market Volatility and Economic Uncertainties
Denali Therapeutics: Focus on Neurological Advancements Amid Market Volatility In the midst of recent stock market fluctuations, Denali Therapeutics remains committed to its mission to advance treatme…
Denali Therapeutics Faces Regulatory Hurdles Amid Evolving FDA Standards for Neurodegenerative Drugs
Navigating Regulatory Challenges: Denali Therapeutics in a Shifting FDA Landscape As Denali Therapeutics advances its drug development pipeline geared towards combating neurodegenerative diseases, the…